- Home
- YQ vs BCTX Comparison
YQ vs BCTX Comparison
Compare YQ & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YQ | BCTX |
|---|---|---|
| Founded | 2012 | 2014 |
| Country | China | Canada |
| Employees | N/A | 4 |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.2M | 26.6M |
| IPO Year | 2020 | 2025 |
Fundamental Metrics
Financial Performance| Metric | YQ | BCTX |
|---|---|---|
| Price | $1.82 | $3.43 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $40.00 |
| AVG Volume (30 Days) | 8.1K | ★ 144.6K |
| Earning Date | 06-09-2026 | 06-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $380.95 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.68 | $0.61 |
| 52 Week High | $6.45 | $14.68 |
Technical Indicators
Market Signals| Indicator | YQ | BCTX |
|---|---|---|
| Relative Strength Index (RSI) | 30.49 | 50.17 |
| Support Level | N/A | $2.98 |
| Resistance Level | $2.60 | $4.51 |
| Average True Range (ATR) | 0.15 | 0.24 |
| MACD | -0.04 | -0.03 |
| Stochastic Oscillator | 9.68 | 24.59 |
Price Performance
Historical ComparisonAbout YQ 17 Education & Technology Group Inc.
17 Education & Technology Group Inc is engaged in providing education and education technology services in the People's Republic of China (PRC) with a focus on the Teaching and Learning SaaS offerings. It offers smart, in-school, teaching and learning SaaS offerings assist students, teachers, schoolmasters and educational authorities across China. It also offer other educational products and services that complement students' in-school learning. Geographically group operates in China.
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.